Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Best Peptides for Complex Regional Pain: Research Comparison

BPC-157 VEGF modulation, NO signalling, endothelial repair Restored blood flow 85% vs 40% in ischaemia models; promotes functional angiogenesis 200–500 mcg/day (animal models, SC) Strongest evidence for microvascular repair. Addresses trophic changes and oedem

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • BPC-157
  • VEGF modulation, NO signalling, endothelial repair
  • Restored blood flow 85% vs 40% in ischaemia models; promotes functional angiogenesis
  • 200–500 mcg/day (animal models, SC)
  • Strongest evidence for microvascular repair. Addresses trophic changes and oedema
  • Cerebrolysin
  • BDNF/CNTF neurotrophic support, microglial modulation
  • Reduced spinal microglial activation 40% in nerve injury models
  • 5–30 mL IV (clinical), dose-dependent
  • Best-supported for central sensitisation. Clinical data in neuropathic pain
  • Thymosin Beta-4
  • Actin sequestration, angiogenesis, nerve regeneration
  • Improved capillary density 60% in ischaemic tissue; promotes functional vessel formation
  • 2–10 mg twice weekly (SC)
  • Targets vascular and nerve repair. Indirect CRPS relevance via tissue healing
  • Dihexa
  • HGF mimetic, synaptogenesis, c-Met receptor agonism
  • 7-fold increase in dendritic spine density; reverses maladaptive plasticity
  • 1–5 mg/day oral (preclinical)
  • Promising for CNS plasticity reversal. Early-stage research only
  • KPV
  • NF-κB inhibition, anti-inflammatory, cytokine suppression
  • Reduced TNF-alpha 70% in inflammation models; blocks inflammatory transcription
  • 500 mcg–2 mg/day (SC or oral)
  • Anti-inflammatory at genetic level. Mechanistically sound but no CRPS-specific trials
  • Thymalin
  • Mast cell stabilisation, T-cell regulation, immune modulation
  • Reduced mast cell tryptase 35% in allergic models; dampens NGF release
  • 10–50 mg IM (clinical protocols)
  • Addresses NGF-driven pain amplification. Indirect evidence only